Merck & Co spearheads move towards outcomes-based healthcare

26 May 2017
merck-700

America’s Merck & Co (NYSE: MRK) is to collaborate with health services company Optum to draft reimbursement models driven by health outcomes data.

The companies are looking to explore models where payments are aligned more closely with the performance of the drug, in terms of the end result for patients.

The use of a value-based, or outcomes-based approach to pricing, long established in the fields of market access and reimbursement in European countries, has not taken off to the same extent in the USA, where there are often fewer pricing pressures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical